Knowledge and Attitudes of Patients and Healthcare Professionals on a Spectrum of Genetic Tests Relevant to Breast Cancer Patients

NCT01619306 | Unknown DMC

• 1 other identifier: 2010/00752
• Study Type: observational
• Target: 850
• Locations: 1 country
• Sites: 1

Brief Summary

Objectives: Primary objectives:

• The investigators aim to conduct a questionnaire survey in a South-East Asian tertiary institution, to assess whether breast cancer patients and their physicians would consider the use of three different kinds of genetic tests currently available to breast cancer patients:
• BRCA1/2 germline testing,
• CYP2D6 genotyping and
• Oncotype DX® testing. Secondary objectives: To explore factors which might influence their decisions on genetic testing, including:
• Acceptability of the tests and anti-cancer management based on the test results
• Reliability and affordability of the test
• Ability of the test to influence treatment decisions
• Broader implications of the test, e.g., psychosocial, financial impact Study design: Cross-sectional study, Survey Questionnaires were developed for 3 categories of individuals:
• Patients with early stage breast cancer
• Healthcare professionals caring for breast cancer patients
• Medical students /cancer researchers The questionnaires for patients and medical students/cancer researchers are similar. The questionnaires contain a brief section on demographic information, interest in and past experience with genetic testing. Three hypothetical situations are described to determine if participants will agree to BRCA1/2 testing, CYP2D6 genotyping and Oncotype DX® testing, respectively. 18 categorical 'yes'/ 'no' questions explore reasons for their decisions. Each scenario requires a short, hand-written response. The questionnaire for healthcare professionals contains a brief section on demographics and past experience with genetic testing. Three hypothetical situations are described to determine if healthcare professionals will recommend their patients for BRCA1/2 testing, CYP2D6 genotyping and Oncotype DX® testing, respectively. 12 categorical questions explore the reasons for their decision, and physicians are required to rank these in order of importance. Distribution of questionnaires: Questionnaires will be handed out to agreeable participants on the following occasions:
• Patients- National University Health System Cancer Centre Level 3 amp; 4 waiting areas
• Medical students - before or after lectures, or at personal contact
• Cancer researchers - before or after lectures, or at personal contact
• Healthcare professionals - before or after NUHS breast tumour board, or at personal contact Due caution will be exercised to ensure that the questionnaire is only handed out to subjects who are aged 21 years and above.

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Conduct a questionnaire survey in a South-East Asian tertiary institution

  The investigators aim to conduct a questionnaire survey in a South-East Asian tertiary institution, to assess whether breast cancer patients and their physicians would consider the use of three different kinds of genetic tests currently available to breast cancer patients: BRCA1/2 germline testing, CYP2D6 genotyping and Oncotype DX® testing.

Secondary Outcomes (1)

• To explore factors which might influence their decisions on genetic testing

Eligibility Criteria

• Age: 21 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Questionnaires will be handed out to agreeable participants on the following occasions. 1. Patients- National University Health System Cancer Centre Level 3 amp; 4 waiting areas 2. Medical students - before or after lectures, or at personal contact 3. Cancer researchers - before or after lectures, or at personal contact 4. Healthcare professionals - before or after NUHS breast tumour board, or at personal contact Due caution will be exercised to ensure that the questionnaire is only handed out to subjects who are aged 21 years and above.

You may qualify if:

• Patients with early stage breast cancer
• Healthcare professionals caring for breast cancer patients
• Medical students /cancer researchers

Sponsors & Collaborators

• National University Hospital, Singapore: lead

Study Sites (1)

Nationa University Hospital

Singapore, Singapore

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Andrea Wong, MRCP

CONTACT

+65 6779 5555; andrea_la_wong@nuhs.edu.sg

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2012
• First Posted: June 14, 2012
• Study Start: January 1, 2011
• Primary Completion: December 1, 2014
• Last Updated: December 11, 2013

Record last verified: 2013-12

Locations

SG (1)